Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
BBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.62 - $39.47
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.88M
Market Cap
$6.44B
Enterprise Value$6.74B
Total Cash (Recent Filing)-$92.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.54
Next Earnings
May 01, 2025EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.85
Shares Outstanding190,188,630
10 Day Avg. Volume3,122,711
30 Day Avg. Volume2,876,737
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.80
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit30.90
Enterprise Value/Ebitda-15.42
Forecast
1Y Price Target
$56.77Price Target Upside67.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst maintains a Buy rating with a price objective of $46, indicating confidence in the stock's potential upside.
Clinical BenefitsEarly signals of improved clinical benefits and Attruby’s lower WAC have been compelling arguments for prescribers to favor Attruby.
FDA ApprovalAcoramidis was approved by the FDA as Attruby™, the first and only approved product for adults with ATTR-CM in the United States.
Bears Say
Operational HurdlesStabilizers are expected to remain a 1L mainstay given prescriber familiarity, pricing, and administrative hurdles.
Prescription LagDespite challenges, there is a reported lag in getting prescribed patients on therapy.
---
Ownership Overview
29.25% Insiders
16.80% Mutual Funds
0.62% Other Institutional Investors
39.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $21.62 and its highest was $39.47 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
BridgeBio Pharma Inc’s market cap is $6.44B.
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is May 01, 2025 which is in 12 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Feb 20, 2025. The company reported -$1.4 earnings per share for the quarter, missing the consensus estimate of -$1.12 by -$0.28.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -0.92.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 190,188,630 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$1.4 in its last earnings report, missing expectations of -$1.12. Following the earnings report the stock price went up 1.405%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Currently, no hedge funds are holding shares in BBIO
---
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.77 (67.61% Upside)
$56.77 (67.61% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $304.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.58%
12-Months-Change
Fundamentals
Return on Equity
35.68%
Trailing 12-Months
Asset Growth
68.26%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering transformative medicines to treat genetic diseases. The company operates in the pharmaceutical sector and specializes in targeting genetic conditions at their source. BridgeBio's portfolio includes a range of drug candidates aimed at addressing various genetic disorders, some of which are in clinical trials. The company's mission is to harness advancements in genetic research to improve patient outcomes.
---
BBIO Stock 12 Month Forecast
Average Price Target
$56.77
▲(67.61% Upside)
Technical Analysis
Sarepta Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
Revolution Medicines
―
Legend Biotech
―
Best Analysts Covering BBIO
1 Year
1 Year Success Rate
14/17 ratings generated profit
1 Year Average Return
+27.43%
reiterated a buy rating 2 months ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +27.43% per trade.
---